Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction

Analytical Biochemistry
Rumin ZhangWilliam Windsor

Abstract

MDM2 is an important negative regulator of the tumor suppressor protein p53 which regulates the expression of many genes including MDM2. The delicate balance of this autoregulatory loop is crucial for the maintenance of the genome and control of the cell cycle and apoptosis. MDM2 hyperactivity, due to amplification/overexpression or mutational inactivation of the ARF locus, inhibits the function of wild-type p53 and can lead to the development of a wide variety of cancers. Thus, the development of anti-MDM2 therapies may restore normal p53 function in tumor cells and induce growth suppression and apoptosis. We report here a novel high-throughput fluorescence polarization binding assay and its application in rank ordering small-molecule inhibitors that block the binding of MDM2 to a p53-derived fluorescent peptide.

References

May 15, 1997·Nature·Y HauptM Oren
May 15, 1997·Nature·M H KubbutatK H Vousden
Jul 22, 1998·Nucleic Acids Research·J MomandJ Niland
Jun 9, 1999·Proceedings of the National Academy of Sciences of the United States of America·W Tao, A J Levine
Nov 13, 1999·Nature Cell Biology·J D WeberD Bar-Sagi
Mar 14, 2000·Molecular and Cellular Biology·J D WeberC J Sherr
Apr 18, 2000·Mutation Research·M S ColmanJ C Barrett
Sep 1, 2000·Journal of Medicinal Chemistry·C García-EcheverríaP Furet
Sep 12, 2000·Nature Cell Biology·S D BoydT Jacks
Sep 12, 2000·Nature Cell Biology·R K GeyerC G Maki
Oct 14, 2000·Archives of Biochemistry and Biophysics·Z LaiR A Copeland
Jul 18, 2001·Journal of the American Chemical Society·S J DuncanM Moore
Aug 22, 2001·Bioorganic & Medicinal Chemistry Letters·C García-EcheverríaP Chène
Jan 16, 2002·Current Opinion in Genetics & Development·Dan Michael, Moshe Oren
Oct 17, 2002·Journal of Molecular Biology·Oliver SchonAlan R Fersht
Feb 4, 2003·Nature Reviews. Cancer·Patrick Chène
Apr 8, 2003·Combinatorial Chemistry & High Throughput Screening·T J BurkeK M Ervin
Apr 18, 2003·Mini Reviews in Medicinal Chemistry·Daniella I ZhelevaPeter M Fischer
Apr 30, 2003·Cell Death and Differentiation·M Oren
Jan 6, 2004·Science·Lyubomir T VassilevEmily A Liu

❮ Previous
Next ❯

Citations

May 2, 2008·Chemical Reviews·Andras Bauer, Brent Stockwell
Feb 17, 2007·Journal of the American Chemical Society·Hai-Feng Chen, Ray Luo
Aug 21, 2008·Journal of the American Chemical Society·Ryan C ClarkDale L Boger
Mar 5, 2011·Nature Protocols·Ana M Rossi, Colin W Taylor
Nov 17, 2009·The Journal of Biological Chemistry·Jason PhanJiandong Chen
Nov 16, 2013·Assay and Drug Development Technologies·Alexander RoheMatthias Schmidt
Dec 1, 2007·Analytical Biochemistry·Ganesh H IyerS Pazhanisamy
Oct 13, 2012·Medicinal Research Reviews·Weisi Wang, Yongzhou Hu
Apr 17, 2008·Analytical Biochemistry·Kimberly J PetersonSamuel H Gellman
Sep 28, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Ute FischerKlaus Schulze-Osthoff
Jul 20, 2007·Nature Chemical Biology·James IngleseDouglas S Auld
Feb 12, 2008·Analytical and Bioanalytical Chemistry·David S Smith, Sergei A Eremin
Mar 1, 2006·International Journal of Peptide Research and Therapeutics·Peter M Fischer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis